SCHEMBL3300883

SCHEMBL3300883

Cc1ccc(=O)n(-c2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
CYP1A2 P05177 1/20 0.56
HPGD P15428 1/20 0.56
BLM P54132 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MAPK14 Q16539 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
BCL2A1 Q16548 1/20 0.40
MEN1 O00255 1/20 0.40
RPA1 P27694 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
CYP11B2 P19099 1/20 0.39
RGS4 P49798 1/20 0.39
RGS8 P57771 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10059735 0.83 ALDH1A1 (0.49) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL356681 0.81 ALDH1A1 (0.80) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3305181 0.80 ALDH1A1 (0.61) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3975362 0.80 ALDH1A1 (0.67) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL10059736 0.79 MAPT (0.47) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3310642 0.79 KDM4E (0.66) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3970272 0.79 ALDH1A1 (0.77) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3305273 0.79 ALDH1A1 (0.59) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL10025186 0.78 KDM4E (0.75) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL3306525 0.76 ALDH1A1 (0.56) KDM4EALDH1A1CYP1A2HPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA DIEREPHARMA, INC. (US) 2010-04-22 US claimed
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES TAO LI JIAN 2009-10-15 US claimed
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases TAO LI J 2009-01-01 US claimed
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases TAO LI J 2007-08-30 US claimed
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA DIEREPHARMA, INC. (US) 2010-04-22 US disclosed
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES TAO LI JIAN 2009-10-15 US disclosed
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases TAO LI J 2009-01-01 US disclosed
US-20080319027-A1 Composition and Method for Treating Fibrotic Diseases TAO LI JIAN 2008-12-25 US disclosed
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases TAO LI J 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA REN, PTPRF, PPM1F KDM4E 280/4885ALDH1A1 341/4885CYP1A2 837/4885
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885
US-20080319027-A1 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES COL1A1, COL2A1, MMP1 KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.